Earlier this year the Innovative Genomics Institute and the life sciences tools conglomerate Danaher launched a collaborative center to develop genome-editing therapies for rare and other diseases. The Danaher-IGI Beacon for CRISPR Cures seeks to address hundreds of diseases with a unified research, development, and regulatory approach. Their goal is to create a new model for the development of genomic medicines. We spoke to Fyodor Urnov, IGI’s director of technology and translation and director of the new Beacon center, about the evolution of gene editing technology, the challenges of a platform approach, and how the organization plans to share what it learns.
Bringing Aberrant Proteins Back into the Fold
A Cat who Curates Rare Mice
Putting the Patient at the Center of Rare Disease Clinical Trials
Creating a Toolkit to Accelerate the Development of Gene Editing Therapies
PTC Looks to Advanced Therapies
Going to Extreme Lengths
Everything’s up to Date in Kansas City, at Least When It Comes to Genomics
Choosing the Right Viral Vector for a Gene Therapy
A Software Platform to Give Patients the Tools to Build Treatments for Rare Genetic Diseases
Side Effects: The Toll a Rare Disease Can Take on a Family in Pursuit of a Cure
Realizing the Potential of CRISPR Gene Editing
Understanding the Economic Toll of Rare Disease in the United States
The Promise of Gene-Based Therapies for Neurodegenerative Conditions
Moving Beyond Viral Vectors for Gene Therapies
Acquisitions Help Jazz Build Toward Commercial Crescendo
Powerful Gene Editing Approach Offers the Promise of Correcting a Range of Rare Diseases
A Child's-Eye-View of Clinical Trials
Using Nanoliposomes to Make Cancer Therapies Safer and More Effective
Accelerating Treatments for Rare Disease through Data Sharing
Treating the Root Cause of Sickle Cell Disease
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
NABOR® TALKS
U.S Property Podcast
Aligned Money Show
The Ramsey Show
Planet Money